Alerts will be sent to your verified email
Verify Email
AUROPHARMA
|
Aurobindo Pharma
|
Alkem Laboratories
|
Glenmark Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
12.72 % | 17.38 % | 3.99 % |
|
5yr Avg Net Profit Margin
|
12.5 % | 14.54 % | 2.85 % |
|
Price to Book
|
1.82 | 5.29 | 6.15 |
|
P/E
|
17.56 | 27.73 | 72.2 |
|
5yr Avg Cash Conversion Cycle
|
-46.37 Days | -61.46 Days | -150.94 Days |
|
5yr Average Interest Coverage Ratio
|
43.54 | 24.48 | 4.25 |
|
5yr Avg ROCE
|
15.27 % | 22.76 % | 17.54 % |
|
5yr Avg Operating Profit Margin
|
19.22 % | 18.44 % | 15.96 % |
|
5 yr average Debt to Equity
|
0.19 | 0.18 | 0.38 |
|
5yr CAGR Net Profit
|
-8.16 % | 6.44 % | 1.54 % |
|
5yr Average Return on Assets
|
8.64 % | 12.47 % | 2.09 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
51.82 % | 53.04 % | 46.65 % |
|
Share Pledged by Promoters
|
17.08 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-0.01 % | -4.1 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
9.14 % | 8.82 % | 9.74 % |
|
Aurobindo Pharma
|
Alkem Laboratories
|
Glenmark Pharma
|
|---|